Utility of Nanosized Microemulsion for Transdermal Delivery of Tolterodine Tartrate: Ex-Vivo Permeation and In-Vivo Pharmacokinetic Studies

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Urology. 2003;61:37–49.

Stewart WF, Van Rooyen JB, Cundiff GW. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.

Irwin DE, Milsom I, Kopp Z. Impact of overactive bladder symptoms on employment, social interactions and emotional wellbeing in six European countries. BJU Int. 2006;97:96–100.

Kaplan SA, Roehrborn CG, Dmochowski R. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68:328–32.

Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid Program. Value Health. 2005;8:495–505.

Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine superior tolerability and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165:1452–6.

Serels SR, Appell RA. Tolterodine: a new antimuscarinic agent for the treatment of the overactive bladder. Expert Opin Investig Drugs. 1999;8(7):1073–8.

Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Hoglund P, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997;35(7):287–95.

Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int. J. Pharm. 2007;332:1–16.

Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv. Colloid Interface Sci. 2006;123–126:369–385.

Kreilgaard M, Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. Pharm Res. 2001;18(5):593–9.

Sintov AC, Botner S. Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems. Int J Pharm. 2006;311(1–2):55–62.

Spiclin P, Homar M, Zupancic-Valant A, Gasperlin M. Sodium ascorbyl phosphate in topical microemulsions. Int J Pharm. 2003;256(1–2):65–73.

Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16(4):249–55.

Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int. J. Pharm. 2001;215(1–2):57–65.

Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152–61.

''Declaration of Helsinki.'' As amended by the 52nd World Medical Assembly (WMA). World Medical Association, Edinburgh, Scotland, October 2000.

International conference of harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline. Guidelines for good clinical practice. May 1996.

Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML. Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm. Res. 1991;8:350–354.

Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery Int. J. of Pharm. 1999;184:1–6.

Mayorga P, Puisieux F, Couarraze G. Formulation study of a transdermal delivery system of primaquine. Int. J. Pharm. 1996;132:71–79.

Zheng XS, Duan CZ, Xiao ZD, Yao BA. Transdermal delivery of praziquantel: effects of solvents on permeation across rabbit skin. Biol Pharm Bull. 2008;31(5):1045–8.

Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov. Today. 2004;9(16):697–703.

Fini A, Bergamante V, Ceschel GC, Ronchi C, De Moraes CA. Control of transdermal permeation of hydrocortisone acetate from hydrophilic and lipophilic formulations. AAPS PharmSciTech. 2008;9(3):762–8.

Menon G.K. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev. 54 (1): S3–17(2002).

Klamerus K, Lee G. Effects of some hydrophilic permeation enhancers on the absorption of bepridil through excised human skin. Drug Dev. and Ind. Pharmacy. 1992;18(13):1411–1422.

M. Kreilgaard, E.J. Pedersen, J.W. Jaroszewski. NMR. characterisation and transdermal drug delivery potential of microemulsion systems. J. Control Rel. 69:421–433 (2000).

H. E. J. Hofland, J. A. Bouwstra, F. Spies, G. Gooris, H. E. Junginger. Interaction between liposomes and human skin in vitro: Poster presentation. Conference: Liposomes in Drug Delivery 21 years On, London, 12–15 (1990).

N. Weiner, K. Egbaria. Topical application of liposomal systems: Poster presentation. Conference: Liposomes in Drug Delivery 21 years On, London, 12–15 (1990).

Kweon JH, Chi SC, Park Transdermal ES. delivery of diclofenac using microemulsions. Arch Pharm Res. 2004;27(3):351–6.

Delgado-Charro MB, Iglesias-Vilas G, Blanco-Mendez J, Lopez-Quintela MA, Marty JP, Guy RH. Delivery of a hydrophilic solute through the skin from novel microemulsion systems. Eur. J. Pharm. Biopharm. 1997;43:37–42.

Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001;40(3):227–35.

Guay D.R.P. Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence Clin Pharmacokinet. 42(14): 1243–1285 (2003).